The fight against Alzheimer's disease is relentless, and the search for effective treatments continues. But what if a common mood stabilizer held the key to slowing cognitive decline? Lithium (LIT), often used to treat bipolar disorder, has shown promising neuroprotective effects in preclinical studies. But does it translate to the real world for Alzheimer's patients? Let's dive in.
Alzheimer's disease (AD) is a devastating neurodegenerative disorder marked by memory loss, behavioral changes, and a significant decline in the quality of life. Despite extensive research, effective treatments that can modify the course of the disease remain elusive. This is where the potential of LIT comes into play. LIT has demonstrated several neuroprotective properties, including the ability to inhibit certain enzymes, reduce the buildup of harmful proteins like amyloid-β and tau, decrease neuroinflammation, and preserve the health of synapses and axons. These findings have sparked interest in LIT as a potential therapeutic strategy to protect cognitive function and slow down the progression of AD.
The Science Behind the Hope
Recent research, like the study by Aron et al. (2025), has shown that naturally occurring LIT in the brain may play a role in maintaining cognitive resilience as we age. In animal models, when LIT levels were depleted, it accelerated cognitive decline and worsened AD-related pathologies. Conversely, supplementing with LIT, especially LIT orotate (LIT-O), which minimizes amyloid binding, seemed to prevent these issues and preserve memory. This suggests that disruptions in LIT balance could be an early event in AD and that restoring LIT levels in the brain could offer therapeutic or preventative benefits.
But here's where it gets controversial... Translating these promising preclinical findings into human treatments requires careful consideration, especially given the safety concerns and limited effectiveness of conventional LIT formulations like LIT carbonate (LIT-C).
Putting LIT to the Test
To address this gap, a team of researchers, led by Professor Taro Kishi from Fujita Health University School of Medicine in Japan, conducted a thorough review and meta-analysis of existing clinical trials. This meta-analysis included six randomized, placebo-controlled trials (RCTs) that involved 435 participants with mild cognitive impairment (MCI) or AD. The trials varied in duration, ranging from 10 weeks to 24 months, and evaluated different LIT formulations, including LIT-C, LIT gluconate, and LIT sulfate. The results were made available online on November 6, 2025 and will be published in Volume 180 of the journal Neuroscience and Biobehavioral Reviews on January 01, 2026.
The primary focus of the analysis was to assess changes in cognitive performance, measured using the Alzheimer's Disease Assessment Scale–Cognitive Subscale. Secondary outcomes included behavioral and psychological symptoms, adverse events, and discontinuation rates. The data were analyzed using statistical methods to account for variations across the studies.
The Results: A Mixed Bag
The meta-analysis revealed that LIT supplementation, in general, did not significantly improve cognitive function compared to a placebo. Professor Kishi noted, "Our meta-analysis showed that LIT, including LIT-C, which was frequently used in clinical practice, did not significantly delay cognitive impairment progression in individuals with MCI and AD compared with placebo." Dr. Matsunaga added that secondary outcomes like behavioral symptoms, adverse events, and discontinuation rates also showed no significant differences between the LIT and placebo groups. Dr. Saito described that the meta-regression analysis showed no link between initial cognitive scores and the effect of LIT on cognitive performance.
Key Takeaways and Future Directions
Prof. Iwata described that "although our meta-analysis demonstrated that no clear clinical benefit was observed with conventional LIT salts, our study offers several important insights." The study highlights potential limitations of commonly used LIT formulations such as LIT-C, which exhibit higher ionization and greater amyloid binding, potentially reducing LIT's bioavailability in the brain. The researchers suggest that alternative formulations, such as LIT-O, might be a better option. "Preclinical studies suggest that alternative formulations like LIT-O maybe a potential alternative as it may cross the blood–brain barrier and enter cells more efficiently than LIT-C, potentially enabling lower dosage requirements and reduced toxicity," added Prof. Kishi, emphasizing the need for future clinical trials to test this newer compound in human populations.
So, what does this all mean? While conventional LIT salts don't seem to slow cognitive decline in MCI or AD patients, the research underscores the importance of exploring alternative LIT formulations and targeted strategies. This meta-analysis provides a valuable bridge between preclinical findings and clinical outcomes, guiding future research toward harnessing LIT's neuroprotective properties safely and effectively. The next step? Well-designed, long-term clinical trials of LIT-O in individuals with early-stage AD or MCI are now needed to determine if LIT can truly make a difference in preventing or slowing the progression of AD.
What are your thoughts on these findings? Do you think alternative LIT formulations hold promise? Share your opinions in the comments below!
